Browse > Article
http://dx.doi.org/10.4142/jvs.2021.22.e77

Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs  

Song, Doo-Won (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Ro, Woong-Bin (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Sur, Jung-Hyang (Department of Veterinary Pathology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Seung, Byung-Joon (Department of Veterinary Pathology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Kang, Hyun-Min (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Kim, Jong-Won (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Park, See-Hyoung (Department of Biological and Chemical Engineering, Hongik University)
Park, Hee-Myung (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
Publication Information
Journal of Veterinary Science / v.22, no.6, 2021 , pp. 77.1-77.10 More about this Journal
Abstract
Background: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. Objectives: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. Methods: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). Results: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5-175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5-79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2-57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6-70.5]) in healthy dogs. Conclusions: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors.
Keywords
Tumors; biomarkers; insulin-like growth factor; insulin-like growth factor binding proteins; dogs;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bergman D, Halje M, Nordin M, Engstrom W. Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology. 2013;59(3):240-249.   DOI
2 Jaillardon L, Abadie J, Godard T, Campone M, Loussouarn D, Siliart B, et al. The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study. BMC Cancer. 2015;15(1):664.   DOI
3 Neumann S, Welling H, Thuere S. Insulin-like growth factor I concentration in dogs with inflammatory and neoplastic liver diseases. J Vet Med A Physiol Pathol Clin Med. 2007;54(10):612-617.   DOI
4 Rossi G, Errico G, Perez P, Rossi G, Paltrinieri S. Paraneoplastic hypoglycemia in a diabetic dog with an insulin growth factor-2-producing mammary carcinoma. Vet Clin Pathol. 2010;39(4):480-484.   DOI
5 Hou YL, Luo P, Ji GY, Chen H. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;33(6):e22912.   DOI
6 Jitpean S, Holst BS, Hoglund OV, Pettersson A, Olsson U, Strage E, et al. Serum insulin-like growth factor-I, iron, C-reactive protein, and serum amyloid A for prediction of outcome in dogs with pyometra. Theriogenology. 2014;82(1):43-48.   DOI
7 Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798-826.   DOI
8 Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 1995;9(3):361-367.   DOI
9 Hu Q, Zhou Y, Ying K, Ruan W. IGFBP, a novel target of lung cancer? Clin Chim Acta. 2017;466:172-177.   DOI
10 Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505-518.   DOI
11 Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215-244.   DOI
12 Finotello R, Ressel L, Arvigo M, Baroni G, Marchetti V, Romanelli G, et al. Canine pancreatic islet cell tumours secreting insulin-like growth factor type 2: a rare entity. Vet Comp Oncol. 2016;14(2):170-180.   DOI
13 Gerke I, Kaup FJ, Neumann S. 26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors. Can J Vet Res. 2018;82(2):115-123.
14 Maniscalco L, Iussich S, Morello E, Martano M, Gattino F, Miretti S, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. Vet J. 2015;205(2):272-280.   DOI
15 Szczubial M, Dabrowski R, Lopuszynski W, Bochniarz M, Krawczyk M, Urban-Chmiel R. Circulating concentrations of insulin like growth factor-1 in female dogs with spontaneous mammary tumours. Med Weter. 2018;74(3):167-170.
16 Grimberg A. P53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab. 2000;70(2):85-98.   DOI
17 Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009;296(5):C954-C976.   DOI
18 Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep. 2016;4(5):609-614.   DOI
19 Strage E, Lewitt M, Lilliehoo I, Stroom-Holst B, Jones B, Fall T. 46. Evaluation of an IGFBP-blocked ELISA for measuring IGF-I in canine serum. Vet Clin Pathol. 2011;40(4):587.
20 Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS One. 2016;11(8):e0161009.   DOI
21 Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res. 2014;24(5):164-173.   DOI
22 Brunke MW, Frye CW, Levine CB, Hansen C, Wakshlag JJ. Insulin-like growth factor-1 and selected insulin-like growth factor binding protein concentrations during an ultramarathon sled dog race. Sci World J. 2016;2016:5686372.   DOI
23 Queiroga FL, Perez-Alenza D, Silvan G, Pena L, Lopes CS, Illera JC. Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci. 2010;89(3):396-403.   DOI
24 Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol. 2008;19(7):1293-1298.   DOI
25 McQuown B, Burgess KE, Heinze CR. Preliminary investigation of blood concentrations of insulin-like growth factor, insulin, lactate and β-hydroxybutyrate in dogs with lymphoma as compared with matched controls. Vet Comp Oncol. 2018;16(2):262-267.   DOI
26 Mehta HH, Gao Q, Galet C, Paharkova V, Wan J, Said J, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154-5163.   DOI
27 Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 2014;4(1):29-41.
28 Le HT, Lee HJ, Cho J, Min HY, Lee JS, Lee SJ, et al. Insulin-like growth factor binding protein-3 exerts its anti-metastatic effect in aerodigestive tract cancers by disrupting the protein stability of vimentin. Cancers (Basel). 2021;13(5):1041.   DOI
29 Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulinlike growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53- deficient mice. Cancer Res. 1997;57(21):4667-4672.